The role for phase separation in oncogenesis and aberrant chromatin looping formation

相分离在肿瘤发生和异常染色质环形成中的作用

基本信息

  • 批准号:
    10908136
  • 负责人:
  • 金额:
    $ 57.28万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-04 至 2027-06-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT Rearrangement of NUP98 gene (NUP98-r) is recurrent in leukemias such as acute myeloid leukemia (AML). Patients with NUP98-r show poor prognosis and therapy failure. Most NUP98-r partners (>30 identified from patients) are a DNA-binding domain of transcription factor (TF; e.g. HOXA9) or a histone-binding motif such as Plant Homeodomain (PHD), suggesting chromatin deregulation as an oncogenic mechanism. NUP98-r fusions invariably retain Phenylalanine-Glycine (FG) repeats, termed intrinsically disordered region (IDR), from NUP98. How unstructured IDR contributes to oncogenesis remains elusive. Our studies of NUP98-HOXA9, an AML NUP98-TF chimera, unveil an essential requirement of NUP98’s IDR for liquid-liquid phase separation (LLPS). We also show that IDR and LLPS are critical for the much-enhanced genome binding by NUP98-HOXA9 and for long-distance chromatin looping between oncogene promoters and enhancers, leading to development of aggressive AML in mice. Our unpublished preliminary studies of other recurrent leukemic fusions (namely, NUP98-PHD fusions and MSI2-HOXA9, a leukemia-related chimera formed by fusing a less-studied IDR of an RNA-binding protein with HOXA9’s DNA-binding domain) all point to involvements of IDR and LLPS for oncogenesis. Thus, we hypothesize that, due to aberrant genic fusions, a number of leukemia-related onco- TFs and chromatin factors acquire a phase-separation-inducing IDR to establish LLPS, which confers chimera a much more enhanced ability in genomic targeting; consequently, an oncogenic gene-expression program is over-activated while aberrant chromatin loops are formed between oncogene promoters and enhancers, which drives formation of aggressive leukemias. Dissection of the mechanisms underlying the IDR- and phase- separation-mediated aberrant genome organization and oncogene activation in cancer cells shall provide new and paradigm-shifting views as for how aggressive cancer develops, implicative of potentially new treatments in future. Towards this goal, we will further characterize the role for the un-studied IDR (that of MSI2) in establishing LLPS in vitro and in cells (Aim 1A) and will use primary human hematopoietic stem/progenitor cells (HSPCs) and derived cells to define roles of IDR and LLPS in regulating genomic targeting (1B), the target gene expression (1C), and leukemic transformation in vitro/vivo (1D) by various fusions (NUP98-PHD and MSI2/NUP98-HOXA9). LLPS-indued chromatin looping is CTCF-independent and represents a previously unstudied mechanism underlying 3D chromatin organization. We will further define the 3D chromatin structure alterations caused by various NUP98-r and MSI2-HOXA9 fusions in disease-relevant cells (Aim 2A), define the molecular mechanisms driving formation/maintenance of LLPS-dependent loops (2B), and determine the impact of LLPS DNA loops on the sustained activation of oncogenes by using a novel CRISPR/dCas9-IDR fusion strategy (2C). As phase-separation-competent molecules are frequently implicated in a wide range of human cancers and diseases, both the significance and overall impact of the project are potentially high.
项目摘要/摘要 NUP98基因重排(NUP98-r)在急性髓系白血病(AML)等白血病中反复出现。 NUP98-r患者预后差,治疗失败。大多数NUP98-r合作伙伴(>30确定自 患者)是转录因子(Tf;例如HOXA9)的DNA结合域或组蛋白结合基序,例如 植物同源域(PHD),提示染色质去调控是致癌机制之一。NUP98-R融合 从NUP98中始终如一地保留苯丙氨酸-甘氨酸(FG)重复序列,称为固有无序区(IDR)。 非结构化IDR如何促进肿瘤发生仍是个未知数。我们对急性髓系白血病NUP98-HOXA9的研究 NUP98-TF嵌合体,揭示了NUP98的S IDR对液-液相分离(LLP)的基本要求。 我们还表明IDR和LLP对于NUP98-HOXA9和NUP98-HOXA9和 用于癌基因启动子和增强子之间的长距离染色质环,导致 小鼠侵袭性急性髓系白血病。我们未发表的其他复发性白血病融合的初步研究(即, NUP98-PHD融合和MSI2-HOXA9,一个与白血病相关的嵌合体,由一个较少研究的IDR融合而成 具有HOXA9‘S DNA结合域的核糖核酸结合蛋白)都表明IDR和LLP参与了 致癌作用。因此,我们假设,由于异常的基因融合,一些与白血病相关的肿瘤- TFS和染色质因子获得相分离诱导的IDR来建立LLP,这赋予了嵌合体 基因组靶向能力大大增强;因此,致癌基因表达程序是 在癌基因启动子和增强子之间形成过度激活而异常的染色质环,这 导致侵袭性白血病的形成。对IDR-和阶段-的潜在机制的剖析- 分离介导的癌细胞异常基因组组织和癌基因激活将提供新的 以及关于癌症如何发展的范式转变观点,暗示可能出现新的治疗方法 在未来。为了实现这一目标,我们将进一步说明未研究的IDR(MSI2)在 在体外和细胞内建立LLP(目标1A),并将使用原代人类造血干/祖细胞 细胞(HSPC)和衍生细胞来确定IDR和LLP在调节基因组靶向中的作用(1B), 靶基因表达(1C)和不同融合(NUP98-PHD)的体外/体内白血病转化(1D) 和MSI2/NUP98-HOXA9)。LLP诱导的染色质循环是独立于CTCF的,并且代表了以前的 3D染色质组织的潜在机制尚未研究。我们将进一步定义3D染色质结构 疾病相关细胞中不同NUP98-r和MSI2-HOXA9融合引起的改变(Aim 2A),定义 驱动LLP依赖环(2B)形成/维持的分子机制,并决定 利用新型CRISPR/dCas9-IDR研究LLP DNA环对癌基因持续激活的影响 融合策略(2C)。由于具有相分离能力的分子经常牵涉到广泛的 对于人类癌症和疾病,该项目的意义和总体影响都可能很高。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Douglas H. Phanstiel其他文献

ALS-associated TDP-43 aggregates drive innate and adaptive immune cell activation
肌萎缩侧索硬化症(ALS)相关的TDP - 43聚集体驱动先天性和适应性免疫细胞活化
  • DOI:
    10.1016/j.isci.2025.112648
  • 发表时间:
    2025-06-20
  • 期刊:
  • 影响因子:
    4.100
  • 作者:
    Baggio A. Evangelista;Joey V. Ragusa;Kyle Pellegrino;Yijia Wu;Ivana Yoseli Quiroga-Barber;Shannon R. Cahalan;Omeed K. Arooji;Jillann A. Madren;Sally Schroeter;Joe Cozzarin;Ling Xie;Xian Chen;Kristen K. White;J. Ashley Ezzell;Marie A. Iannone;Sarah Cohen;Douglas H. Phanstiel;Rick B. Meeker;Todd J. Cohen
  • 通讯作者:
    Todd J. Cohen
Proximity-dependent recruitment of Polycomb repressive complexes by the lncRNA emAirn/em
长链非编码 RNA emAirn 依赖于邻近性招募 Polycomb 抑制复合物
  • DOI:
    10.1016/j.celrep.2023.112803
  • 发表时间:
    2023-07-25
  • 期刊:
  • 影响因子:
    6.900
  • 作者:
    Aki K. Braceros;Megan D. Schertzer;Arina Omer;Jackson B. Trotman;Eric S. Davis;Jill M. Dowen;Douglas H. Phanstiel;Erez Lieberman Aiden;J. Mauro Calabrese
  • 通讯作者:
    J. Mauro Calabrese

Douglas H. Phanstiel的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Douglas H. Phanstiel', 18)}}的其他基金

The role for phase separation in oncogenesis and aberrant chromatin looping formation
相分离在肿瘤发生和异常染色质环形成中的作用
  • 批准号:
    10652637
  • 财政年份:
    2022
  • 资助金额:
    $ 57.28万
  • 项目类别:
The role for phase separation in oncogenesis and aberrant chromatin looping formation
相分离在肿瘤发生和异常染色质环形成中的作用
  • 批准号:
    10539807
  • 财政年份:
    2022
  • 资助金额:
    $ 57.28万
  • 项目类别:
MECHANISMS OF DYNAMIC CHROMATIN LOOPING DURING DIFFERENTIATION
分化过程中动态染色质环的机制
  • 批准号:
    10415986
  • 财政年份:
    2018
  • 资助金额:
    $ 57.28万
  • 项目类别:
MECHANISMS OF DYNAMIC CHROMATIN LOOPING DURING DIFFERENTIATION
分化过程中动态染色质环的机制
  • 批准号:
    10198946
  • 财政年份:
    2018
  • 资助金额:
    $ 57.28万
  • 项目类别:
Mechanisms of Dynamic Chromatin Looping During Differentiation - Common Fund Data Supplement
分化过程中动态染色质循环的机制 - 共同基金数据补充
  • 批准号:
    9983342
  • 财政年份:
    2018
  • 资助金额:
    $ 57.28万
  • 项目类别:

相似海外基金

Computing analysis of leukemic stem cell dynamics in acute myelocytic leukemia
急性粒细胞白血病白血病干细胞动力学的计算分析
  • 批准号:
    19K08356
  • 财政年份:
    2019
  • 资助金额:
    $ 57.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Generation of immunotoxins with super-targeting mAb in the acute myelocytic leukemia
在急性髓细胞白血病中使用超靶向单克隆抗体产生免疫毒素
  • 批准号:
    23501309
  • 财政年份:
    2011
  • 资助金额:
    $ 57.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
  • 批准号:
    3556971
  • 财政年份:
    1980
  • 资助金额:
    $ 57.28万
  • 项目类别:
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
  • 批准号:
    3556968
  • 财政年份:
    1980
  • 资助金额:
    $ 57.28万
  • 项目类别:
ERADICATION OF ACUTE MYELOCYTIC LEUKEMIA CELLS BY MAB THERAPY
通过 MAB 疗法根除急性粒细胞白血病细胞
  • 批准号:
    3889304
  • 财政年份:
  • 资助金额:
    $ 57.28万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了